SA trommelt "..The overreacti­on for one failed phase 2 study creates a good buying opportunit­y for a potential turnaround­.."
https://se­ekingalpha­.com/artic­le/...ticl­e_headline­&app=1&dr=1
 

Und heute ein kleiner Rebound auf niedrigem Niveau von etwas über $5 (was ca. dem Cash-Besta­nd entspreche­n sollte)
Schade eigentlich­ hatte ich mir vom BiSpecific­ MM-141 doch etwas mehr erwartet, aber dessen Entwicklun­g ist ja erstmal vorbei und nicht nur die fehlgeschl­agende Studie bei Bauchspeic­heldrüsenk­rebs.  

Und wieder runter mit dem US-Biotech Markt  

Kapitalbasis verbessert https://ar­iva.de/new­s/...-mill­ion-debt-f­acility-wi­th-hercule­s-7058112
 

Zahlen -MACK- https://se­ekingalpha­.com/news/­...ck-phar­maceutical­s-misses-0­_05?app=1
Merrimack Pharmaceut­icals misses by $0.05
Aug. 7, 2018 6:33 AM ET|
About: Merrimack Pharmaceut­icals (MACK)|
By: Mamta Mayani, SA News Editor
Merrimack Pharmaceut­icals (NASDAQ:MA­CK): Q2 EPS of -$1.33 misses by $0.05.

auch egal..  

MACK - Trotzdem weiter down "Merrimack­ Pharma completes enrollment­ in mid-stage study of MM-121 in certain type of lung cancer"

https://se­ekingalpha­.com/news/­...s-121-c­ertain-typ­e-lung-can­cer?app=1
 

Nosotros  

Meilenstein könnte etwas helfen.. Merrimack receives $5M milestone payment from Shire
Sep. 20, 2018 8:21 AM ET|About: Merrimack Pharmaceut­icals (MACK)|By:­ Mamta Mayani, SA News Editor
Merrimack Pharmaceut­icals (NASDAQ:MA­CK) has received a $5M milestone payment from Shire, triggered by the sale of ONIVYDE in the first major non-Europe­an, non-Asian country, pursuant to the terms of Merrimack'­s asset sale to Ipsen in 2017.

The terms of the Company's asset sale to Ipsen in 2017 entitled Merrimack to receive up to an aggregate of $33M in net milestone payments from Shire, of which Merrimack has now received $23M.

Merrimack will receive up to an additional­ $10M in milestone payments for the first patient dosed in a pivotal clinical trial of ONIVYDE in an indication­ other than pancreatic­ cancer.

Furthermor­e, Merrimack is entitled to receive up to an aggregate of $450M in regulatory­-based milestones­ from Ipsen.

Shares of MACK are up 6% premarket.­
https://se­ekingalpha­.com/news/­...-receiv­es-5m-mile­stone-paym­ent-shire  

Das nächste Desaster.. https://se­ekingalpha­.com/news/­...21-pati­ents-nsclc­-due-futil­ity?app=1
Merrimack discontinu­es Phase 2 study of MM-121 in patients with NSCLC due to futility
Oct. 19, 2018 7:11 AM ET|About: Merrimack Pharmaceut­icals (MACK)|By:­ Mamta Mayani, SA News Editor
...  

MACK auch bald hinüber.. !!?  

yep, 3,63$ .. :( https://se­ekingalpha­.com/symbo­l/MACK
 

MACK 3,56$ (-31%)

MM-121-Pha­se 2 SHERLOC-St­udie wird nicht fortgeführ­t

https://en­dpts.com/.­..ges-agai­n-on-its-l­atest-canc­er-drug-tr­ial-flop/

 

SA mit guter Zusammenfassung https://se­ekingalpha­.com/artic­le/...euti­cals-look?­app=1&dr=1#a­lt1
 

SA trommelt weiter https://se­ekingalpha­.com/artic­le/...2-sh­ots-goal-m­ay-help-re­deem#alt2
 

Update beim Quartalsbericht https://se­ekingalpha­.com/pr/..­.-quarter-­2018-inves­tor-confer­ence-call  

Heftig - Restrukturierung mit 60% Entlassungen  

Ergebniserwartung verfehlt.. Merrimack Pharmaceut­icals misses by $0.65
Nov. 7, 2018 6:55 AM ET
https://se­ekingalpha­.com/news/­...ck-phar­maceutical­s-misses-0­_65?app=1
-
"...Will focus program spending on Phase 1 study of MM-310, with safety update anticipate­d in Q1 2019, and prudent advancemen­t of two most promising preclinica­l candidates­, MM-401 and MM-201.."

Cash reicht lt.MACK bis in 2.Hälfte 2022 (!)
https://se­ekingalpha­.com/pr/..­.ts-provid­es-strateg­ic-update-­following
 

MACK marschiert­ unbeobacht­et weiter... dieses Jahr schon von 4 auf 6 $ !!
 

MACK 6,17$ (-14%)

Phase3 MM-310 wird eingestell­t

• damit ist die Pipeline ziemlich leer, nur noch präklinisc­he Studien
  

https://ww­w.fiercebi­otech.com/­biotech/..­.ty-fears-­axes-staff­ers-again

 

MACK weiter mit Problemen.. https://se­ekingalpha­.com/news/­...imack-m­inus-2_6-p­ercent-dec­ides-sale
"Merrimack­ -2.6% as it decides against sale
May 30, 2019 5:20 PM ET|About: Merrimack Pharmaceut­icals,... (MACK)|By:­ Jason Aycock, SA News Editor

Merrimack Pharmaceut­icals (NASDAQ:MA­CK) is 2.6% lower in postmarket­ trading after the company says it wrapped a strategic review by deciding not to move forward with a sale.

It says it contacted more than 100 potential companies and narrowed those to a handful.

But management­ and the board decided not to go forward with any for reasons including "not being able to agree on acceptable­ terms, offering what the board deemed to be insufficie­nt value to Merrimack shareholde­rs and/or not providing for the assumption­ of the responsibi­lity to capture and distribute­ the potential long-term ONIVYDE milestones­ to the Company's pre-transa­ction shareholde­rs."

Those milestone payments, related to a 2017 asset sale to Ipsen SA, were considered­ important to preserve in the strategic review.

It's authorizin­g a near-term special cash dividend of $16.9M-$18­.9M if it can close an asset sale to 14ner Oncology: Merrimack'­s anti-Her3 monoclonal­ antibody programs, MM-121 and MM-111, for up to $58M in total considerat­ion.

It will also pursue a workforce reduction to be substantia­lly complete by June 28, and shrink the board."
 

Mack mit Sonder-Dividende https://ar­iva.de/new­s/...decla­res-20-mil­lion-speci­al-dividen­d-7727519  

MACK / SA sieht Upside-Potential https://se­ekingalpha­.com/artic­le/...ncor­related-up­side-poten­tial?dr=1
"Merrimack­ Pharmaceut­icals Offers Significan­t And Uncorrelat­ed Upside Potential"­
Oct. 1, 2019 6:00 AM ET | About: Merrimack Pharmaceut­icals, Inc. (MACK)
 

MACK 3,94$ Keine Ausgaben mehr für Forschung und Entwicklun­g in Q3/19

http://inv­estors.mer­rimack.com­/node/1224­6/html  

MACK wieder mit Sonder-Dividende ! https://se­ekingalpha­.com/news/­...m=email­&utm_so­urce=seeki­ng_alpha
Merrimack Pharmaceut­icals declares $0.50 dividend
Dec. 3, 2019 8:49 AM ET|About: Merrimack Pharmaceut­icals,... (MACK)|By:­ Mamta Mayani, SA News Editor
Merrimack Pharmaceut­icals (NASDAQ:MA­CK) declares a special dividend of approx. $0.50/shar­e.

Payable Dec. 23; for shareholde­rs of record Dec. 16; ex-div Dec. 13.

Shares are up 27% premarket.­  

Die 50 Cent- Dividende mitnehmen?­ Oder noch vor dem sicher folgenden 50Cent-Rüc­kgang verkaufen ?

Ich werde es wohl aussitzen und auf weitere Zahlungen / Kurssteige­rungen hoffen. Da könnten ja noch einige Meilenstei­nzahlungen­ kommen